Skip to main content
Erschienen in: International Urology and Nephrology 11/2019

30.09.2019 | Nephrology - Original Paper

The relationship between R wave peak time and left ventricular mass index in patients with end-stage renal disease on hemodialysis

verfasst von: Macit Kalçık, Mucahit Yetim, Tolga Doğan, Barış Eser, İbrahim Doğan, Lütfü Bekar, Oğuzhan Çelik, Yusuf Karavelioğlu

Erschienen in: International Urology and Nephrology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cardiovascular complications have been reported to be the main cause of mortality in patients with end-stage renal disease (ESRD). Although left ventricular hypertrophy is the most common clinical presentation of cardiac remodeling, cardiovascular complications may also include disturbances of the heart conduction system. The R wave peak time (RWPT) has been previously associated with left ventricular hypertrophy and myocardial ischemia. In this study, we aimed to investigate the relationship between RWPT and echocardiographic parameters in patients with ESRD.

Methods

This study enrolled 66 patients (29 females, age 57.2 ± 12.8 years) with ESRD, and 72 controls (37 females, age 55.3 ± 10.1 years) with similar risk factors. All patients underwent electrocardiography and transthoracic echocardiography. The RWPT was defined as the interval between the onset of the QRS complex and the peak of the R or R′ wave.

Results

There was no significant difference in terms of clinical and demographic parameters between ESRD patients and controls. Left ventricular ejection fraction was similar between the groups. However, left atrial diameter, interventricular septal thickness, posterior wall thickness, left ventricular mass (LVM) and left ventricular mass index (LVMI) were significantly higher in patients with ESRD. Among electrocardiographic parameters, P wave and QRS complex durations and RWPT were significantly higher in patients with ESRD. Prolonged RWPT, increased LVM and LVMI were identified as associates of ESRD. Furthermore, RWPT correlated well with LVM and LVMI.

Conclusion

The present study demonstrated that RWPT prolonged significantly in patients with ESRD. Furthermore, prolonged RWPT has been associated with increased LVM and LVMI.
Literatur
1.
Zurück zum Zitat Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191–197PubMedCrossRef Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191–197PubMedCrossRef
2.
Zurück zum Zitat Saeed F, Arrigain S, Schold JD, Nally JV Jr, Navaneethan SD (2019) What are the risk factors for one-year mortality in older patients with chronic kidney disease? An analysis of the cleveland clinic CKD registry. Nephron 141(2):98–104PubMedCrossRef Saeed F, Arrigain S, Schold JD, Nally JV Jr, Navaneethan SD (2019) What are the risk factors for one-year mortality in older patients with chronic kidney disease? An analysis of the cleveland clinic CKD registry. Nephron 141(2):98–104PubMedCrossRef
3.
Zurück zum Zitat Wang AY (2007) Cardiovascular risk factors in peritoneal dialysis patients revisited. Perit Dial Int 27(Suppl 2):S223–S227PubMedCrossRef Wang AY (2007) Cardiovascular risk factors in peritoneal dialysis patients revisited. Perit Dial Int 27(Suppl 2):S223–S227PubMedCrossRef
4.
Zurück zum Zitat García-López E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P (2007) Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int 27(Suppl 2):S205–S209PubMedCrossRef García-López E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P (2007) Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int 27(Suppl 2):S205–S209PubMedCrossRef
5.
Zurück zum Zitat Hampl H, Riedel E (2009) Cardiac disease in the dialysis patient: good, better, best clinical practice. Blood Purif 27:99–113PubMedCrossRef Hampl H, Riedel E (2009) Cardiac disease in the dialysis patient: good, better, best clinical practice. Blood Purif 27:99–113PubMedCrossRef
6.
Zurück zum Zitat Rodriguez M, Lorenzo V (2009) Progress in uremic toxin research: parathyroid hormone, a uremic toxin. Semin Dial 22:363–368PubMedCrossRef Rodriguez M, Lorenzo V (2009) Progress in uremic toxin research: parathyroid hormone, a uremic toxin. Semin Dial 22:363–368PubMedCrossRef
7.
Zurück zum Zitat MacLeod AG, Wilson FN, Barker PS (1930) The form of the electrocardiogram. I. Intrinsicoid electrocardiographic deflections in animals and man. Exp Biol Med 27:586–587CrossRef MacLeod AG, Wilson FN, Barker PS (1930) The form of the electrocardiogram. I. Intrinsicoid electrocardiographic deflections in animals and man. Exp Biol Med 27:586–587CrossRef
8.
Zurück zum Zitat Pérez-Riera AR, de Abreu LC, Barbosa-Barros R, Nikus KC, Baranchuk A (2016) R-peak time: an electrocardiographic parameter with multiple clinical applications. Ann Noninvasive Electrocardiol 21:10–19PubMedCrossRef Pérez-Riera AR, de Abreu LC, Barbosa-Barros R, Nikus KC, Baranchuk A (2016) R-peak time: an electrocardiographic parameter with multiple clinical applications. Ann Noninvasive Electrocardiol 21:10–19PubMedCrossRef
9.
Zurück zum Zitat Holland RP, Brooks H (1976) The QRS complex during myocardial ischemia. An experimental analysis in the porcine heart. J Clin Invest 57:541–550PubMedPubMedCentralCrossRef Holland RP, Brooks H (1976) The QRS complex during myocardial ischemia. An experimental analysis in the porcine heart. J Clin Invest 57:541–550PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Rencüzoğulları I, Çağdaş M, Karakoyun S et al (2018) The association between electrocardiographic R wave peak time and coronary artery disease severity in patients with non-ST segment elevation myocardial infarction and unstable angina pectoris. J Electrocardiol 51(2):230–235PubMedCrossRef Rencüzoğulları I, Çağdaş M, Karakoyun S et al (2018) The association between electrocardiographic R wave peak time and coronary artery disease severity in patients with non-ST segment elevation myocardial infarction and unstable angina pectoris. J Electrocardiol 51(2):230–235PubMedCrossRef
11.
Zurück zum Zitat Çağdaş M, Karakoyun S, Rencüzoğullari İ et al (2017) Relationship between R-wave peak time and no-reflow in ST elevation myocardial infarction treated with a primary percutaneous coronary intervention. Coron Artery Dis 28:326–331PubMedCrossRef Çağdaş M, Karakoyun S, Rencüzoğullari İ et al (2017) Relationship between R-wave peak time and no-reflow in ST elevation myocardial infarction treated with a primary percutaneous coronary intervention. Coron Artery Dis 28:326–331PubMedCrossRef
12.
Zurück zum Zitat Scharer K, Schmidt KG, Soergel M (1999) Cardiac function and structure in patients with chronic renal failure. Pediatr Nephrol 13:951–965PubMedCrossRef Scharer K, Schmidt KG, Soergel M (1999) Cardiac function and structure in patients with chronic renal failure. Pediatr Nephrol 13:951–965PubMedCrossRef
13.
Zurück zum Zitat McCullough PA, Assad H (2012) Diagnosis of cardiovascular disease in patients with chronic kidney disease. Blood Purif 33:112–118PubMedCrossRef McCullough PA, Assad H (2012) Diagnosis of cardiovascular disease in patients with chronic kidney disease. Blood Purif 33:112–118PubMedCrossRef
14.
Zurück zum Zitat Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305PubMedCrossRef Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305PubMedCrossRef
15.
Zurück zum Zitat Saran R, Robinson B, Abbott KC et al (2017) US renal data system 2016 annual data report: epidemiology of Kidney Disease in the United States. Am J Kidney Dis 69(3 Suppl 1):A7–A8PubMedPubMedCentralCrossRef Saran R, Robinson B, Abbott KC et al (2017) US renal data system 2016 annual data report: epidemiology of Kidney Disease in the United States. Am J Kidney Dis 69(3 Suppl 1):A7–A8PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Eckardt KU (1999) Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transpl 14:1317–1323CrossRef Eckardt KU (1999) Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transpl 14:1317–1323CrossRef
17.
Zurück zum Zitat Juan-Garcia I, Puchades MJ, Sanjuan R et al (2012) Echocardiographic impact of hydration status in dialysis patients. Nefrologia 32:94–102PubMed Juan-Garcia I, Puchades MJ, Sanjuan R et al (2012) Echocardiographic impact of hydration status in dialysis patients. Nefrologia 32:94–102PubMed
18.
Zurück zum Zitat Poulikakos D, Ross L, Recio-Mayoral A et al (2014) Left ventricular hypertrophy and endothelial dysfunction in chronic kidney disease. Eur Heart J Cardiovasc Imaging 15:56–61PubMedCrossRef Poulikakos D, Ross L, Recio-Mayoral A et al (2014) Left ventricular hypertrophy and endothelial dysfunction in chronic kidney disease. Eur Heart J Cardiovasc Imaging 15:56–61PubMedCrossRef
19.
Zurück zum Zitat Ky B, Shults J, Keane MG et al (2013) FGF23 modifies the relationship between vitamin D and cardiac remodeling. Circ Heart Fail 6:817–824PubMedCrossRef Ky B, Shults J, Keane MG et al (2013) FGF23 modifies the relationship between vitamin D and cardiac remodeling. Circ Heart Fail 6:817–824PubMedCrossRef
20.
Zurück zum Zitat London GM, Fabiani F, Marchais SJ et al (1987) Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 31:973–980PubMedCrossRef London GM, Fabiani F, Marchais SJ et al (1987) Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 31:973–980PubMedCrossRef
23.
Zurück zum Zitat Paoletti E, De Nicola L, Gabbai FB et al (2016) Associations of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension. Clin J Am Soc Nephrol 11:271–279PubMedCrossRef Paoletti E, De Nicola L, Gabbai FB et al (2016) Associations of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension. Clin J Am Soc Nephrol 11:271–279PubMedCrossRef
24.
Zurück zum Zitat Eckardt KU, Scherhag A, Macdougall IC et al (2009) Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol 20:2651–2660PubMedPubMedCentralCrossRef Eckardt KU, Scherhag A, Macdougall IC et al (2009) Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol 20:2651–2660PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Paoletti E, Specchia C, Di Maio G et al (2004) The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transpl 19:1829–1834CrossRef Paoletti E, Specchia C, Di Maio G et al (2004) The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transpl 19:1829–1834CrossRef
26.
Zurück zum Zitat Tsao CW, Gona PN, Salton CJ et al (2015) Left ventricular structure and risk of cardiovascular events: a Framingham Heart Study cardiac magnetic resonance study. J Am Heart Assoc 4(9):e002188PubMedPubMedCentralCrossRef Tsao CW, Gona PN, Salton CJ et al (2015) Left ventricular structure and risk of cardiovascular events: a Framingham Heart Study cardiac magnetic resonance study. J Am Heart Assoc 4(9):e002188PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Herzog CA, Asinger RW, Berger AK et al (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving global outcomes (KDIGO). Kidney Int 80:572–586PubMedCrossRef Herzog CA, Asinger RW, Berger AK et al (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving global outcomes (KDIGO). Kidney Int 80:572–586PubMedCrossRef
28.
Zurück zum Zitat Ritz E (2009) Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int 75:771–773PubMedCrossRef Ritz E (2009) Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int 75:771–773PubMedCrossRef
29.
Zurück zum Zitat Martin LC, Franco RJ, Gavras I et al (2004) Association between hypervolemia and ventricular hypertrophy in hemodialysis patients. Am J Hypertens 17:1163–1169PubMedCrossRef Martin LC, Franco RJ, Gavras I et al (2004) Association between hypervolemia and ventricular hypertrophy in hemodialysis patients. Am J Hypertens 17:1163–1169PubMedCrossRef
30.
Zurück zum Zitat McRae JM, Levin A, Belenkie I (2006) The cardiovascular effects of arteriovenous fistulas in chronic kidney disease. A cause for concern? Semin Dial 19:349–352CrossRef McRae JM, Levin A, Belenkie I (2006) The cardiovascular effects of arteriovenous fistulas in chronic kidney disease. A cause for concern? Semin Dial 19:349–352CrossRef
31.
Zurück zum Zitat Gross ML, Ritz E (2008) Hypertrophy and fibrosis in the cardiomyopathy of uremia—beyond coronary heart disease. Semin Dial 21:308–318PubMedCrossRef Gross ML, Ritz E (2008) Hypertrophy and fibrosis in the cardiomyopathy of uremia—beyond coronary heart disease. Semin Dial 21:308–318PubMedCrossRef
32.
Zurück zum Zitat Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R (2007) Role of aldosterone in left ventricular hypertrophy among African–American patients with end-stage renal disease on hemodialysis. Am J Nephrol 27:159–163PubMedCrossRef Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R (2007) Role of aldosterone in left ventricular hypertrophy among African–American patients with end-stage renal disease on hemodialysis. Am J Nephrol 27:159–163PubMedCrossRef
33.
Zurück zum Zitat Di Lullo L, Gorini A, Russo D, Santoboni A, Ronco C (2015) Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med. 5(4):254–266PubMedPubMedCentralCrossRef Di Lullo L, Gorini A, Russo D, Santoboni A, Ronco C (2015) Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med. 5(4):254–266PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Savard P, Rouleau JL, Ferguson J et al (1997) Risk stratification after myocardial infarction using signal-averaged electrocardiographic criteria adjusted for sex, age, and myocardial infarction location. Circulation 96:202–213PubMedCrossRef Savard P, Rouleau JL, Ferguson J et al (1997) Risk stratification after myocardial infarction using signal-averaged electrocardiographic criteria adjusted for sex, age, and myocardial infarction location. Circulation 96:202–213PubMedCrossRef
35.
Zurück zum Zitat Shenkman HJ, Pampati V, Khandelwal AK et al (2002) Congestive heart failure and QRS duration: establishing prognosis study. Chest 122:528–534PubMedCrossRef Shenkman HJ, Pampati V, Khandelwal AK et al (2002) Congestive heart failure and QRS duration: establishing prognosis study. Chest 122:528–534PubMedCrossRef
36.
Zurück zum Zitat Grant RP, Dodge HT (1956) Mechanisms of QRS complex prolongation in man; left ventricular conduction disturbances. Am J Med 20:834–852PubMedCrossRef Grant RP, Dodge HT (1956) Mechanisms of QRS complex prolongation in man; left ventricular conduction disturbances. Am J Med 20:834–852PubMedCrossRef
37.
Zurück zum Zitat Hamilin RL, Pipers FS, Hellerstein HK, Smith CR (1968) QRS alteration immediately following production of left ventricular free wall ischemia in dogs. Am J Physiol 215:1032–1040CrossRef Hamilin RL, Pipers FS, Hellerstein HK, Smith CR (1968) QRS alteration immediately following production of left ventricular free wall ischemia in dogs. Am J Physiol 215:1032–1040CrossRef
38.
Zurück zum Zitat Ozer N, Aytemir K, Atalar E et al (2000) P wave dispersion in hypertensive patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 23:1859–1862PubMedCrossRef Ozer N, Aytemir K, Atalar E et al (2000) P wave dispersion in hypertensive patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 23:1859–1862PubMedCrossRef
39.
Zurück zum Zitat Turhan H, Yetkin E, Senen K et al (2002) Effects of percutaneous mitral balloon valvuloplasty on P-wave dispersion in patients with mitral stenosis. J Cardiol 89(5):607–609CrossRef Turhan H, Yetkin E, Senen K et al (2002) Effects of percutaneous mitral balloon valvuloplasty on P-wave dispersion in patients with mitral stenosis. J Cardiol 89(5):607–609CrossRef
40.
Zurück zum Zitat Turhan H, Yetkin E, Atak R et al (2003) Increased P-wave duration and P-wave dispersion in patients with aortic stenosis. Ann Noninvasive Electrocardiol 8(1):18–21PubMedCrossRefPubMedCentral Turhan H, Yetkin E, Atak R et al (2003) Increased P-wave duration and P-wave dispersion in patients with aortic stenosis. Ann Noninvasive Electrocardiol 8(1):18–21PubMedCrossRefPubMedCentral
41.
Zurück zum Zitat Senen K, Turhan H, Riza Erbay A et al (2004) P-wave duration and P-wave dispersion in patients with dilated cardiomyopathy. Eur J Heart Fail 6:567–569PubMedCrossRef Senen K, Turhan H, Riza Erbay A et al (2004) P-wave duration and P-wave dispersion in patients with dilated cardiomyopathy. Eur J Heart Fail 6:567–569PubMedCrossRef
42.
Zurück zum Zitat Boles U, Almuntaser I, Brown A, Murphy RR, Mahmud A, Feely J (2010) Ventricular activation time as a marker for diastolic dysfunction in early hypertension. Am J Hypertens 23(7):781–785PubMedCrossRef Boles U, Almuntaser I, Brown A, Murphy RR, Mahmud A, Feely J (2010) Ventricular activation time as a marker for diastolic dysfunction in early hypertension. Am J Hypertens 23(7):781–785PubMedCrossRef
43.
Zurück zum Zitat Mitsnefes MM, Kimball TR, Kartal J et al (2005) Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism. J Am Soc Nephrol 16:2796–2803PubMedCrossRef Mitsnefes MM, Kimball TR, Kartal J et al (2005) Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism. J Am Soc Nephrol 16:2796–2803PubMedCrossRef
44.
Zurück zum Zitat Jono S, Nishizawa Y, Shioi A, Morii H (1997) Parathyroid hormone related peptide as a regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17:1135–1142PubMedCrossRef Jono S, Nishizawa Y, Shioi A, Morii H (1997) Parathyroid hormone related peptide as a regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17:1135–1142PubMedCrossRef
45.
Metadaten
Titel
The relationship between R wave peak time and left ventricular mass index in patients with end-stage renal disease on hemodialysis
verfasst von
Macit Kalçık
Mucahit Yetim
Tolga Doğan
Barış Eser
İbrahim Doğan
Lütfü Bekar
Oğuzhan Çelik
Yusuf Karavelioğlu
Publikationsdatum
30.09.2019
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 11/2019
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02297-w

Weitere Artikel der Ausgabe 11/2019

International Urology and Nephrology 11/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.